Introduction
jr.· i· . · ™ *™ · ^ j · _ j defective apolipoprotein B-100 is a recently described Familial defective apolipoprotein B-100 is a recently disease, only a few subjects have been described in identified, autosomal dominantly inherited genetic the literature (3 -11) . The total number of identified disorder which leads to increased serum levels of low unrelated subjects is at the moment less than 100, density lipoprotein (LDL) cholesterol (1) . Apolipo-worldwide. The apolipoprotein B-100 mutation inprotein B-100 is the sole protein constituent of LDL creases the LDL-cholesterol, but there exists a wide particles and is responsible for the recognition of LDL range of LDL-cholesterol levels among the subjects, particles by the LDL receptor. In familial defective The plasma of an individual heterozygous for the apolipoprotein B-100, a G to A mutation at nucleic mutation contains two populations of LDL particles, acid 10708 in exon 26 results in the substitution of The increased serum LDL concentration is due to an glutamine for arginine at amino acid position 3500. accumulation of defective LDL particles containing This mutation decreases the binding of LDL to the the mutant apolipoprotein B-100. The implications LDL receptor by more than 95% and causes an for artherosclerosis of the plasma enrichment of deaccumulation of defective LDL particles in serum (2) . fectively binding LDL particles cannot be determined The prevalence of familial defective apolipoprotein B-with certainty from the limited number of identified 100 was estimated to be approximately one in 500 subjects. (3 -5) , making it one of the most common singlegene mutations. The high frequency and the occur-Recently we described a method for identifying subrence of the mutation in several different populations jects with familial defective apolipoprotein B-100 (12) . raise questions concerning its origin. Because familial We report here the results of screening 398 subjects.
The biochemical and clinical data of 12 unrelated subjects heterozygous for familial defective apolipoprotein B-100 and their affected and unaffected family members is presented.
Subjects and Methods

Subjects
A group of 252 unrelated patients with type Ha hypercholesterolaemia (LDL cholesterol > 4.66 mmol/1) were investigated for familial defective apolipoprotein B-100. All individuals were recruited from the outpatient lipid clinic of the Institute of Clinical Chemistry at the University of Cologne. According to their LDL-cholesterol concentration the hypercholesterolaemic patients were divided into three subgroups (tab. 1). By studying the kindred of 8 affected patients, 32 additional subjects were collected and screened for the apolipoprotein B-100 mutation. A second group of 146 normolipidaemic subjects was also studied for familial defective apolipoprotein B-100.
Determination of plasma lipids, lipoproteins and apolipoprotein E genotypes
Blood samples were obtained after an overnight fast. Total serum cholesterol, lipoprotein cholesterol and serum triacylglycerols were determined by enzymatic assays (Boehringer, Mannheim, Germany). Very low density lipoproteins (VLDL) were separated by preparative ultracentrifugation according to Havel et al. (13) . High density lipoprotein (HDL) cholesterol was determined in the VLDL-free infranatant after precipitation of apolipoprotein B-100-containing lipoproteins (Boehringer, Mannheim, Germany). The apolipoprotein E genotypes were determined by the method of Hixson & Vernier (14) .
Detection of the arginine^soo) -» glutamine mutation Genomic DNA was prepared from total blood by using the Triton X-100 lysis method (15) . DNA was amplified by the polymerase chain reaction and the G to A mutation at nucleic acid 10708 was detected by restriction enzyme isoform genotyping. The method employed was recently described in detail (12) .
Determination of genotypes
Four DNA markers were used for the genotyping. These markers consisted of 3 biallelic restriction fragment length polymorphism markers (Xbal, Mspl, EcoRl) { ) and a multi-alleuc marker ( fig. 1 ). The restriction fragment length polymorphism markers were assayed by polymerase chain reaction and digestion with the restriction enzymes, following agarose gel electrophoresis. The multi-allelic marker consisted of a variable number of tandem repeats. The number of repeats was determined by agarose gel electrophoresis. The used nomenclature applied for the 3'hypervariable region was that of Boerwinkle et al. (16) . If family members of an identified subject were available, haplotypes were constructed by analysis of segregation of the polymorphic sites. All polymerase chain reactions were carried out in a final volume of 100 μΐ using 1 μg DNA, 0.25 mmol/1 of each nucleotide, 2.5 units Ta^-polymerase 1 ) (Perkin-Elmer Cetus, Langen, Germany) and the buffer recommended by the manufacturer of the Taq polymerase. For the Xbal-and EcoRlpolymerase chain reaction 0.2 μηιοΐ/ΐ and 0.4 μηιοΐ/l primer were used; for the Ms/?I-polymerase chain reaction and the hypervariable region-polymerase chain reaction 0.15 μπιοΐ/ΐ and 0.1 μηιοΐ/l, respectively. The primer sequences are described elsewhere (1, 16 -18) . The initial denaturation was at 94 °C for 2 minutes, followed by annealing at 55 °C for 1 minute and extension at 72 °C for 1 minute. The next 30 cycles were performed in the same way, except that the denaturing time was changed to 1 minute. The arginineosoo) -* glutamine mutation was not detected in the normolipidaemic group. In the hypercholesterolaemic group, 12 patients were identified who were heterozygous for familial defective apolipoprotein B-100 (tab. 1). The mutation was found in all 3 subgroups of LDL-cholesterol concentration.
Results
Enzymes
Relatives of 8 subjects were available for family studies. Within these families we identified 14 additional subjects with the apolipoprotein B-100 mutation. The biochemical characteristics and the clinical signs of atherosclerosis of the 12 index patients, their relatives with familial defective apolipoprotein B-100 and their unaffected relatives are summarized in table 2. All affected subjects had elevated total cholesterol concentrations in plasma. The cholesterol concentrations ranged from 6.60 mmol/1 to 14.89 mmol/1, mean value 9.43 mmol/1. Hyperlipidaemia was also found in subjects without familial defective apolipoprotein B-100. In 2 subjects, one from the F. S. family and the other from the Ε. Κ. family, hyperlipidaemia might be secondarily caused by diabetes mellitus. The subject from the W. E. family had moderate hypercholesterolaemia which was first manifest postmenopausal. Hypercholesterolaemia of other causes was also observed in the H. K. and H. A. family. Premature atherosclerosis was found in 4 of the 26 subjects with familial defective apolipoprotein B-100. Severe coronary obstructions warranted, in 3 patients, a coronary artery bypass graft. The age of operation was 52 and 60 for the two females and 20 for the male. The fourth patient had suffered a myocardial infarction at age 61. The oldest patient was 92 years of age and had no symptoms of coronary heart disease or peripheral atherosclerosis. In the unrelated probands, arcus cornea was present in 45%, and xanthoma of the Achilles tendon or the extensor tendon of the finger were found in 36%.
In an attempt to find the reason for the variable degree of LDL-cholesterol elevation we determined the apolipoprotein Ε genotypes in the 26 affected patients (tab. 2). One patient had the genotype E2/ The haplotypes were determined by 3 diallelic markers and one hypervariable multi-allelic marker ( fig. 1 ).
The hypervariable region at the 3'-end of the gene comprises 12 resolvable alleles containing different numbers of 15-base pair tandemly repeated sequences. The analysis of haplotypes of the 8 kindred is illustrated in figure 2 . In 7 of the 8 families the haplotypes of the mutant allele were determined unambiguously. The haplotypes of the mutant were in all cases identical, characterized by the presence of the Mspl restriction site (Mspl + ), the absence of the Xbal (Xbal~) and EcoRl (EcoRl~) restriction sites and 49 of the 15 base pair repeats of the hypervariable region (HVR-49). In the remaining 5 individuals with familial defective apolipoprotein B-100, the combination of genotypes was consistent with the presence of the mutation on the above described haplotype. 
Discussion
With the recently described modified polymerase chain reaction technique (12) we screened 252 unrelated individuals with hypercholesterolaemia and 146 normolipidemic controls. In the hypercholesterolaemic group 12 unrelated individuals heterozygous for familial defective apolipoprotein B-100 were identified. The frequency of the mutation was, therefore, about 5% in the hypercholesterolaemic group. In normolipidaemic subjects the mutation was not detected. Assuming a frequency of type Ila hypercholesterolaemia of 5/100 (19), a crude estimate of the frequency of familial defective apolipoprotein B-100 would be 1/400 in the general population and is thus similar to the frequency of familial hypercholesterolaemia which is characterized by defects in the LDLreceptor.
The study of biochemical characteristics and signs of atherosclerosis revealed a considerable variability of expression in patients with heterozygous familial defective apolipoprotein B-100, exemplified by patients W. E. and S. W. (tab. 2). S. W. had severe hypercholesterolaemia and premature atherosclerosis. He warranted a coronary bypass graft at age 20 and had stenosis of the carotis. In contrast, W. E. had only moderate hypercholesterolaemia, the total cholesterol concentrations ranging in the last 10 years from 5.70 to 7.25 mmol/1. Over the whole period she was treated only with diet. Her HDL-cholesterol concentration was at the lower end of the reference range for women. The patient is now 92 years old and has no symptoms of coronary heart disease or peripheral atherosclerosis. Obviously, in patients with familial defective apolipoprotein B-100, atherosclerosis was more advanced in those with severe hypercholesterolaemia than in patients with moderate hypercholesterolaemia. In addition to hypercholesterolaemia, other risk factors, such as smoking as seen in patients S. W. and E. K., may contribute to the progression of atherosclerosis. In summary, it is not the apolipoprotein B-100 mutation per se but the degree of cholesterol elevation and the combination with other risk factors that seem to determine the atherosclerosis risk. Premature atherosclerosis was found in only 4 out of 26 cases. Compared with the atherosclerosis risk of familial hypercholesterolaemia (20) , it seems that the risk in patients with familial defective apolipoprotein B-100 might be somewhat lower, even in patients with severe hypercholesterolaemia. For example, atherosclerosis was present in only one of 4 females older than 60 years with total cholesterol concentrations near or above 10.36 mmol/1. In familial hypercholesterolaemia, HDL cholesterol concentrations are slightly lower on the average than those in normal subjects (20) . In the patients studied with familial defective apolipoprotein B-100, the mean HDL cholesterol was 1.26 mmol/1 and is thus similar to that of normal subjects. The higher HDL-cholesterol concentration of subjects with familial defective apolipoprotein B-100 in comparison with familial hypercholesterolaemia might be a reason for the possibly lower atherosclerosis risk. However, more patients have to be evaluated to estimate the atherosclerosis risk.
The variability of biochemical and clinical characteristics within families was much less than between unrelated subjects. For example, in the S.W. family all affected persons had severe hypercholesterolaemia, and premature atherosclerosis was present in a second case (tab. 2). On the other hand, all affected individuals of the W. E. family had total cholesterol concentrations below the mean value of the unrelated affected subjects, and in 2 cases the concentrations were even below the 95th percentile (19) . In this family the affected individuals were more than 60 years old and no symptoms of atherosclerosis were observed. In an attempt to find reasons for the variable expression of LDL-cholesterol levels we determined the apolipoprotein E genotypes, but a consistent relation between the concentration of LDL-cholesterol and the apolipoprotein E genotype was not observed. The apolipoprotein E genotype E3/E3 was detected in 21 subjects. This group contained individuals with moderate and severe hypercholesterolaemia. At the moment it can only be speculated as to which factors influence the expression of familial defective apolipoprotein B-100 in these patients. But the existence of a relatively large number of affected individuals provides an excellent model for studying the influence of other gene loci and environmental factors on the level of LDL cholesterol and atherosclerosis. The families of 8 index patients were studied to determine the haplotype of the arginine (3 5oo) -» glutamine mutation ( fig. 2) . Seven of the 8 families were informative, and the mutation could be assigned to the haplotype Xbal~9 Msp + , EcoRI~ and HVR-49. In the remaining 5 index patients, the combination of genotypes was consistent with the described haplotype. Because the haplotype of the mutation is very rare (21) , it is likely that the mutation arose from a single origin, rather than being the result of random mutations. Identical haplotypes of the mutation have also been described in other European populations (6, 8, 9) and in a North American population of European origin (3, 17) . This suggests that the mutation has a common European origin. The mutation was not detected in the genetically isolated population of Finland (22) . Further studies of the frequency will show whether a founder population exists in Europe.
